VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%

VOLITIONRX LTD

2026-Q1 EPS reported -$0.97 revenue$985,076

Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).
Received first order for Nu.Q Cancer assays for lung cancer clinical certification.
Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).
Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.